share_log

Annovis Announces New Publication in a Peer-Reviewed Journal

Annovis Announces New Publication in a Peer-Reviewed Journal

Annovis宣布在同行评审期刊上发表新文章
Annovis Bio ·  05/21 00:00

Tue, 21 May 2024

2024 年 5 月 21 日,星期二

MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen (or buntanetap) across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases.

宾夕法尼亚州马尔文,2024年5月21日(GLOBE NEWSWIRE)——开发神经退行性疾病新疗法的临床阶段药物平台公司Annovis Bio, Inc.(纽约证券交易所代码:ANVS)(“Annovis” 或 “公司”)宣布发表一篇新文章,重点比较不同物种中Posiphen(或buntanetap)的药代动力学特征同行评审期刊 生物分子 作为其中的一部分 特刊:淀粉样蛋白在神经系统疾病中的作用

"This publication is a testament to many years of research at Annovis. While we have conducted numerous studies to advance our Posiphen pipeline, this is the first systematic and comprehensive comparison in multiple animal and human samples," says Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Consolidating all this data into one publication offers a more holistic view of Posiphen, enhancing our understanding of its mechanisms."

“这份出版物证明了Annovis多年的研究。尽管我们已经进行了大量研究以推进Posiphen产品线,但这是首次对多个动物和人类样本进行系统和全面的比较。” Annovis创始人、总裁兼首席执行官Maria Maccecchini博士说。“将所有这些数据整合到一份出版物中,可以更全面地了解Posiphen,从而增进我们对其机制的理解。”

Summary: This article synthesizes findings from various preclinical and clinical studies on Posiphen's absorption and metabolism from mice, rats, dogs, and humans. The aim was to better understand the differences in the drug's pharmacokinetic behavior, identify which animal models most closely mimic human responses, and explore the potential clinical implications of these variations.

摘要:本文综合了关于小鼠、大鼠、狗和人类对Posiphen吸收和代谢的各种临床前和临床研究的结果。目的是更好地了解药物药代动力学行为的差异,确定哪些动物模型最能模仿人类反应,并探索这些变异的潜在临床影响。

Key highlights:

主要亮点:

  • Posiphen quickly reaches peak concentration in plasma, followed by high absorption in the brain and cerebrospinal fluid (CSF).
  • Posiphen metabolizes into two primary metabolites: N1-norposiphen and N8-norposiphen.
  • Both Posiphen and its metabolites exhibit rapid clearance in animal models and human subjects; however, in the CSF or the brain, the drug stays longer.
  • Posiphen's absorption, distribution, metabolism, and excretion are similar in healthy volunteers and patients with Alzheimer's and Parkinson's diseases.
  • Posiphen在血浆中迅速达到峰值浓度,随后在大脑和脑脊液(CSF)中吸收率很高。
  • Posiphen 代谢成两种主要代谢物:n1-norposiphen 和 n8-norposiphen。
  • Posiphen及其代谢物在动物模型和人体受试者中均表现出快速清除率;但是,在脑脊液或大脑中,药物的停留时间更长。
  • Posiphen在健康志愿者和阿尔茨海默氏症和帕金森氏病患者中的吸收、分布、代谢和排泄相似。

The article can be found on the journal's website via the link.

该文章可通过以下方式在该期刊的网站上找到 链接

About Annovis Bio, Inc.

关于 Annovis Bio, Inc.

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's Disease (AD), Parkinson's Disease (PD), and other chronic neurodegenerative diseases. It is believed to be the only company developing a drug for both AD and PD designed to inhibit more than one neurotoxic protein to restore axonal and synaptic activity. By improving brain function, the company's goal is to treat memory loss and dementia associated with AD as well as body and brain dysfunction associated with PD. For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and X (formerly known as Twitter).

Annovis Bio, Inc. 总部位于宾夕法尼亚州马尔文,是一家临床阶段的药物平台公司,致力于治疗神经变性,例如阿尔茨海默氏病(AD)、帕金森氏病(PD)和其他慢性神经退行性疾病。据信它是唯一一家同时开发AD和PD药物的公司,该药物旨在抑制一种以上的神经毒性蛋白质,以恢复轴突和突触活性。通过改善大脑功能,该公司的目标是治疗与AD相关的记忆力减退和痴呆以及与PD相关的身体和大脑功能障碍。有关Annovis Bio的更多信息,请访问该公司的网站 www.annovisbio.co 然后关注我们 领英X(以前称为 Twitter)。

Forward-Looking Statements

前瞻性陈述

This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation, the Company's plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those implied by forward-looking statements, including regarding patient enrollment, the effectiveness of Buntanetap and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety and tolerability of buntanetap. See also additional risk factors set forth in the Company's periodic filings with the SEC, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

本新闻稿包含经修订的1933年《证券法》第27A条和经修订的1934年《证券交易法》第21E条所指的 “前瞻性” 陈述。除历史事实陈述以外的所有陈述均可被视为前瞻性陈述。该公司建议谨慎对待前瞻性陈述。前瞻性陈述包括但不限于公司与临床试验相关的计划。这些陈述涉及已知和未知的风险、不确定性和其他因素,这些因素可能导致实际结果与前瞻性陈述所暗示的结果存在重大差异,包括患者入组、Buntanetap的有效性以及公司评估buntanetap疗效、安全性和耐受性的临床试验的时机、有效性和预期结果。另请参阅公司向美国证券交易委员会提交的定期文件中列出的其他风险因素,包括但不限于公司向美国证券交易委员会提交的10-K表年度报告和10-Q表季度报告中 “风险因素” 部分中列出的风险和不确定性。本新闻稿中的所有前瞻性陈述均基于公司截至本申报之日获得的信息。除非适用法律要求,否则公司明确表示不承担任何更新或修改其前瞻性陈述的义务,无论是由于新信息、未来事件还是其他原因。

Investor Contact:
Maria Maccecchini, Ph.D.
maccecchini@annovisbio.com

投资者联系人:
玛丽亚·马切基尼博士
maccecchini@annovisbio.com

Primary Logo

Source: Annovis Bio Inc.

资料来源:Annovis Bio Inc.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发